Stay updated on Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Enrollment status updated to No longer looking for participants and new user-help sections added; study section headings updated (Intervention/Treatment) with a new revision tag (Revision: v3.6.0) and dates.
    Difference
    0.3%
    Check dated 2026-06-12T01:17:37.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision: v3.5.5 was added, replacing Revision: v3.5.4 on the page, indicating a new version of the page without substantive content changes.
    Difference
    0.0%
    Check dated 2026-06-04T16:45:00.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    The page’s revision label has been updated from v3.5.3 to v3.5.4, indicating a newer build of the page. This update reflects a version change rather than a substantive alteration to the study details.
    Difference
    0.0%
    Check dated 2026-05-21T08:43:17.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    A new MARIPOSA publication citation (Lazertinib versus Osimertinib in EGFR-mutant NSCLC; J Thorac Oncol 2025) was added on 2026-05-08. Additionally, May 2026 date entries were added (2026-05-07 and 2026-05), and April 2026 entries (2026-04-22, 2026-04-09, 2026-04) were removed.
    Difference
    0.1%
    Check dated 2026-05-14T01:46:42.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The study locations section was updated to add new sites in China and Turkey and to increase the total number of locations to 269; several previously listed sites were removed (Beijing Cancer Hospital, Hunan Cancer Hospital, Ankara 6560, Gazi University Hospital, National Cancer Institute, The Royal Marsden NHS Trust), reflecting a revision to the study's site roster.
    Difference
    0.3%
    Check dated 2026-04-28T14:37:54.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page revision/version indicator was updated from v3.5.0 to v3.5.2. No study content or key details were changed.
    Difference
    0.0%
    Check dated 2026-04-21T09:28:51.000Z thumbnail image

Stay in the know with updates to Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Amivantamab Combo vs. Osimertinib in NSCLC Clinical Trial page.